Background
HCC is one of the most common malignant tumors in the world, and its mortality has increased year by year [
1]. Deaths caused by HCC worldwide has increased at a greater rate compared to all other cancer [
2]. The advanced cancer-stage patients were treated with chemotherapy or radiation which can be used along with surgery. However, these therapeutic protocols frequently result in the occurrence of drug resistance in the cancer cells to the treatment [
3,
4]. Therefore, it is particularly important to identify more efficient treatment for HCC.
Deubiquitinase is involved in the regulation of cell cycle progression, signal transduction pathway regulation, gene expression, DNA damage repair and chromosome segregation [
5,
6]. USP7 is a member of the deubiquitinating enzymes families and contains five consecutive ubiquitin-like regions (UBLs) [
7]. USP7 was involved in host-virus interaction, DNA damage and repair, gene expression and protein function regulation, immunization and others cellular process [
8]. USP7 plays a multifaceted role and is involved in the development of a variety of tumors, including esophagus cancer, myeloma and ovarian cancer [
9‐
11]. USP7 also regulated the expression of a variety of tumor suppressor genes. In cancer, USP7 could stabilize MDM2 by de-ubiquitination and subsequently promotes degradation of P53 specifically [
12]. Moreover, USP7 impacts mainly on the nuclear activities of PTEN and FOXO, which were forced to the nucleus by USP7 inhibition and sufficient to induce cancer cells apoptosis [
13,
14]. In HCC, USP7 was highly expressed in cancer tissues [
15]. USP7 could inhibit the ubiquitination of P65 and stabilize the expression of P65, thereby promoting the progress of hepatoma cancer [
16]. In addition, reported data supports that USP7 can be used as a new independent prognostic factor for liver cancer [
17]. However, compared to extensive studies regarding USP7 in several other cancers, the function of USP7 in HCC remains to be fully addressed.
In recent years, due to the critical role of USP7, its inhibitors have been interested for cancer treatment. Earlier studies showed that the small molecule compounds HBX 41,108 were regulated the expression of P53 by inhibiting the de-ubiquitination activity of USP7 and suppressed the growth of cancer cells [
18]. The USP7 inhibitor P5091 inhibits Ewing’s sarcoma growth and extends survival time by combined with other treatments [
19]. Recently, a novel small molecule (P22077) that specifically inhibits the function of USP7 has been developed. In vitro assays indicate that P22077 showed low dose inhibitory activity against cancer cell lines via a p53-dependent and p53-independent mechanism [
20]. In addition, not only the tumor cell growth was significantly delayed after knocking down USP7, but also the cellular toxicity of paclitaxel and docetaxel but not carboplatin and cisplatin was enhanced significantly [
21]. However, it is still unknown whether P22077 has therapeutic potential in the treatment of HCC. Here, we revealed an important role of USP7 in HCC and targeting USP7 might be an efficient way to kill HCC cells. The USP7 inhibitor also has synergetic effect with chemotherapeutic drug in the killing of HCC.
Materials and methods
HCC tissue and cells
The HCC fresh tissue from HCC patients (Affiliated hospital of Nantong University). The liver cell (LO2) and HCC cells (SMMC-7721, SK-Hep1, HepG2, Huh7) were purchased from ATCC (USA). LO2 was cultured in 1640 DMEM + 10% FBS. HCC cells were cultured in DMEM + 10% FBS. All cells lines were cultured in 37 °C with 5% CO2 concentration.
Immunohistochemistry (IHC) and evaluation
The paraffin-embedded tissues sections from 100 matched pairs of liver adenocarcinoma and nonmalignant liver tissue of the same patients. The tissues were heated at 60 °C for 45 min and deparaffinized using a graded ethanol series. Then, these tissue sections were incubated in sodium citrate buffer and heated for antigen retrieval and endogenous peroxidase activity was blocked by soaking in 0.3% hydrogen peroxide. USP7 (Santa Cruz, CA, USA) was incubated for 1 h at room temperature. The second antibody was then incubated. All sections were counterstained with hematoxylin, dehydrated and evaluated. Staining of USP7 in the tissues was reviewed and scored independently by two pathologists blinded to the clinical data. The intensity of immunostaining was documented as 0–3 (0, negative; 1, weak; 2, moderate; 3, strong). The percentage of immunoreactive cells was documented as 1 (0–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%). Under these conditions, the optimum cut-off value of samples were respectively classified as low and high expression USP7 by receiver operating curve (ROC) analysis. The area under the curve (AUCs) at different cut-off values of USP7 for different years of overall survival time were calculated.
Antibodies and reagents
The USP7 inhibitor P22077 and Doxorubicin (Dox) was purchased from Selleckchem (Houston, TX, USA), dissolved and diluted in dimethyl sulfoxide (DMSO; Sigma, St. Louis, MO, USA), and stored at − 20 °C, DOX was keep from light. The antibodies were used in Western Blot: anti-USP7 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-H3, anti-H3K4me2, anti-Bax, anti-GAPDH (Cell Signaling Technology, Inc, Beverly, MA, USA).
Western blot analysis
The whole cell lysates come from the cell which were treatment with USP7 inhibitor for 48 h at the indicated doses, and was measured using western blot analysis. The protein were subjected to SDS-PAGE and transferred to PVDF membranes (New England Nuclear, Boston, MA,USA). Subsequently,the PVDF was membranes was blocked with 5% nonfat dry milk with TBS-T which containing Tris-buffered saline and 0.1% Tween-20. Probed with the primary antibodies. After washing with them TBS-T buffer, the cell lysates were incubated with the secondary antibody. The chemiluminescence system (Bio-Rad, USA) was used to detect the protein expression.
CRISPR- sgRNA construction
We designed two sgRNA to knock out the potential sequence of USP7. The vector plasmids were digested by BSPQI enzyme (New England Biolads) at 50 °C for one hour. The sense and antisense sgRNA oligos targeting the predicted super-enhancer locus were annealed at 90 °C for 20 min followed by cooling at room temperature for an hour. The annealing buffer was as following: 10 mM Tris (pH 7.5), 1 mM EDTA and 50 mM NaCl. The ligation was executed with T4 DNA ligase (New England Biolads) at 16 °C overnight. All plasmids were validated by using enzyme digestion and direct DNA sequencing.
Cell transfection
Place the cells into a 6-well plate at the appropriate density. After the cells adhere to the cells within 24 h, transfection is performed. Lipofectamine 2000 was diluted in DMEM medium at various concentrations to find the optimal transfection dose per cell. Mix appropriate amounts of DNA and Lipofectamine 2000 with a little DMEM, respectively, and incubate for 5 min at room temperature. Finally, the DNA was mixed with Lipofectamine 2000 and incubated for 15 min, then added to the cell culture medium, and the medium was changed 6 h after transfection. Due to the high transfection efficiency of the HEK293T cell line, all of our SgRNA transfection was performed first in HEK293T cells. After confirming its knockout in HEK293T cells, stable cell lines with corresponding knockouts will be established in tumor cells.
Establishment of stable cell lines
To construct stable USP7 knockout cell line, SK-hep1 cells and Huh7 cells were transfected by SgUSP7-1, SgUSP7-2 plasmids and transfected by epi-CRISPR vector plasmid as control. After 48 h of transfection, the medium was changed by complete medium containing 1 μg/ml puromycin (InvivoGen). Puromycin-containing medium was further used for additional 2 weeks to select the resistant cells until the stable cell line was established, and always use a concentration of 0.5 μg/ml puromycin to maintain.
Cellular immunofluorescence assays
Suitable cells were in 24-well plate treated with P22077 for 12 h, subsequently, cells treated with Dox at indicated doses for 48 h. Cells were fixed by 4% Paraformaldehyde after the cells rinsed by PBS for 3 times. Cells were closed with Triton X-100 for 30 min and then using anti-USP7 antibody at overnight. After washing with the PBS, the cells were stained with fluorescent dyes (Themorfer, USA) for 2 h and take photos from the light.
CCK-8 assays
The cell proliferation and viability were detected by the cell counting kit-8 (CCK-8; Best Bio, Shanghai, China) assay. Cells were inoculated into 96-well plates at a density of 2 × 104/well and cultivated for 24 h. Each well incubated with CCK-8 reagents for another at the same time on consecutive days. Last, the automated plate reader was used to read the absorbance at a wavelength of 450 nm.
Flow cytometric assays
Cells were treated with P22077 or Dox for 48 h were prepared for the apoptosis detection assay. Cells were washed in PBS at least three times, resuspended in 195 μl of binding buffer and incubated with Annexin V-fluorescein isothiocyanate (Best Bio, Shanghai, China) for 15 min in the dark. By followed, cells were incubated with PI (Best Bio, Shanghai, China) in the dark for 5 min, then analysed by flow cytometry (Beckman Coulter Inc., USA) processes.
500–1000 cells in a six-well plate were incubated for 24 h and then p22077 were added to stimulating the cells for 2 weeks. Colonies which were formed macroscopic, fixed by 4% Paraformaldehyde for 2 h and the purple crystal were used to color. The colonies were counted and calculated compared with the control group.
Wound healing assay
The Scratch assays was used to examined the migration of the cell treated with P22077 at indicated doses for 24 h or 48 h. Subconfluent cells of each group were scraped using sterilized 10 µl pipette tips, washed with PBS, and cultured in six-plated. Wound healing was observed under the microscope (USA) and capture the images.
Allograft assay
Four week old male nude mice were purchased from Nantong University Animal Center (Nantong, China) and the SK-Hep1 cell were injected in specific pathogen-free conditions for 5 × 106 cells into left flank of the nude mice. The nude mice were divided into two groups contained the control group and the experimental group with three mice. P22077 was injected into mice at the dose of 10 mg/kg by intraperitoneal injection of the experimental group. All mice were sacrificed after 6 weeks. Tumors were removed, weighed, and fixed in formalin for the subsequent analysis.
Statistical analysis
All statistical analyses were carried out using GraphPad version 5.0 (Graph Pad software, USA). Significance was analyzed using SPSS 15.0 and student’s t-test. All data are shown as means and standard errors of the mean. P < 0.05 was considered indicate a statistically significant.
Discussion
Hepatocellular carcinoma (HCC) is one of the major malignancies in the world [
22]. Surgical resection is still the main method of treating HCC [
23]. Targeted therapy involving regorafenib, lenvatinib, cabozantinib and ramucirumab has also made great progress [
24]. But the rapid development of HCC patients with poor prognosis and morbidity are increasing for years [
25]. Therefore, it is urgent to find novel therapeutic strategies to improve patients’ survival.
Expression of deubiquitylase USP7 is reported to be a prognostic factor in osteogenic sarcoma, T-cell lymphoma and ovarian cancers [
26‐
28]. Both the mRNA and protein expressions were obviously increased in HCC which is partly consistent with our results [
29]. The higher expression of USP7 is correlated with poorer survival time. Datas indicated that the USP7 inhibitor P5091 was overcoming bortezomib resistance in multiple myelomas by destabilizing NEK2 [
30]. However, few studies have reported on another USP7 novel inhibitor P22077. P22077 was reported to induce apoptosis and efficiently inhibit tumor growth USP7-HDM2-p53 axis in neuroblastoma [
31]. We got the similar results in HCC cells that P22077 can suppress cell growth. We also observed P22077 treatment could greatly induce dead cells that positive for both Annexin V and PI. The phosphatidylserine (PS) is a lipid that normally restricted to the inner leaflet of the plasma membrane. However during apoptosis, PS exposed on the outer leaflet due to loss of lipid asymmetry. Fluorescently labeled Annexin V can bind to PS and be used to detect PS to measure early and late apoptotic cells. While necrotic cells also show stained with Annexin V due to ruptured membranes that permit Annexin V to access the entire plasma membrane. Therefore, both late apoptotic cells and necrotic cells show positive for Annexin V and PI. Further experiments will be taken to distinguish between late apoptosis or necrosis after P22077 treatment.
Drug resistance is a key factor in poor prognosis for HCC patients. The USP7 inhibitor P5091 has been reported to induce apoptosis of multiple myeloma (MM) cells, and synergistic anti-MM effects can be exerted by multiple drugs. In addition, P5091 inhibits tumor growth and synergizes with other chemotherapeutic agents such as lenalidomide, HDAC inhibitor or dexamethasone to induce synergistic anti-multiple myeloma effect [
32,
33].Our data shows P22077 significantly enhances the sensitivity and overcomes resistance of Dox in HCC. Together, we postulate that therapeutic targeting of USP7, using either P22077 or Dox, in patients with HCC may be most effective as an adjuvant therapy.
From the mechanistic aspect, Huh7 cell was treated with P22077 and detected by MS. We found the down-regulated proteins were strongly associated with translational initiation, protein targeting to membrane and viral transcription. These results indicated P22077 restrained HCC proliferation by control the transcription of some oncogenes. In the previous report, P22077 significantly suppressed the growth of human neuroblastoma cell lines which MYCN was amplified [
34]. Notably, the up-regulated proteins were involved in signal transduction and cell proliferation. It suggested that P22077 regulates the growth of HCC by various pathway. Obviously, the histone H3 was distinctly decreased, H3K4me
2 is a methylated form that is involved in the regulation of epigenetics. Western Blot shows H3 and H3K4me
2 were high expression in SK-Hep1 and Huh7 cells. These results indicated P22077 play an anti-proliferation role in HCC through labializing H3 and H3K4me
2 with dependent USP7 function. Considerable literature, USP7 was located in nuclear by immunofluorescence, and H3 was a nucleoprotein which usually used be a marker [
35]. Histone methylation is an inevitable part of histone modification, including H3K4 monomethylation (H3K4me
1), H3K4 demethylation (H3K4me
2), H3K4 trimethylation (H3K4me
3), H3K9me, H3K27me, H3K36me
3, H3K79me, and H3K79me
2 [
36‐
38], which involves a variety of biological processes [
39]. Therefore, we suspect that the lethal effect of P22077 on liver cancer cells by inhibiting USP7 deubiquitinating of H3, the specific mechanism remains to be further studied.
In summary, our study is the first to report the potential of USP7 inhibitor P22077 therapy for liver cancer. It has shown that P22077 may hold a great promise as a therapeutic drug to improve the outcome of hepatic carcinoma patients. P22077 is able to inhibit cell proliferation and colony formation in response to the marked inhibition of H3 and H3K4me2 in HCC. Given the broad inhibition of P22077 and the antitumor effect in HCC, we suggest P22077 may possess therapeutic potential in the treatment of liver cancer. The above studies indicate that another new direction for the development of such drugs will be the development of synergistic double or even multiple inhibitors, and more deubiquitinases and corresponding inhibitors may be found in the future, making targeted drug therapy for tumors a promising reality.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.